PE20090893A1 - Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5 - Google Patents

Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5

Info

Publication number
PE20090893A1
PE20090893A1 PE2008001255A PE2008001255A PE20090893A1 PE 20090893 A1 PE20090893 A1 PE 20090893A1 PE 2008001255 A PE2008001255 A PE 2008001255A PE 2008001255 A PE2008001255 A PE 2008001255A PE 20090893 A1 PE20090893 A1 PE 20090893A1
Authority
PE
Peru
Prior art keywords
alkyl
ring
atoms
piperidin
phenyl
Prior art date
Application number
PE2008001255A
Other languages
English (en)
Inventor
Johannes Aebi
Luke Green
Guido Hartmann
Hans P Maerki
Patrizio Mattei
Fabienne Ricklin
Olivier Roche
Alfred Binggeli
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090893A1 publication Critical patent/PE20090893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDO A DERIVADOS DE PIRAZOL DE FORMULA (I): DONDE (*) ES UN HETEROCICLILO QUE ES UN RESTO MONOCICLICO NO AROMATICO DE 4-8 ATOMOS EN EL ANILLO EN EL QUE UNO O DOS ATOMOS DEL ANILLO SON ATOMOS DE NITROGENO, LOS DEMAS ATOMOS DEL ANILLO SON ATOMOS DE CARBONO; CON LA CONDICION QUE SI (*) CONTIENE EL SEGUNDO ATOMO DE NITROGENO EN EL ANILLO, ENTONCES DICHO ATOMO DE NITROGENO DEL ANILLO NO ESTA UNIDO DIRECTAMENTE A OTRO HETEROATOMO NI A UN GRUPO CARBONILO; X ES (A), (B) O (C); Y ES FENILO O HETEROARILO, SUSTITUIDO POR ALQUILO(C1-C8), HALO-ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS; R1, R2, R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6), HALO-ALQUILO(C1-C6), ENTRE OTROS; R5 ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), TRIMETILSILANIL-ALQUILO(C1-C6), ENTRE OTROS; R6 ES H, ALQUILO(C1-C6), HETEROALQUILO; ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [3,5-DIMETIL-1-(5-TRIFLUORMETIL-PIRIDIN-3-IL)-1H-PIRAZOL-4-IL]-(4-PIRROLIDIN-1-IL-PIPERIDIN-1-IL)-METANONA, [5-CICLOPROPIL-3-METIL-1-(3-TRIFLUORMETOXI-FENIL)-1H-PIRAZOL-4-IL]-(4-PIRROLIDIN-1-IL-PIPERIDIN-1-IL)-METANONA, 7-{1-[5-CICLOPROPIL-3-METIL-1-(3-TRUFLUORMETOXI-FENIL)-1H-PIRAZOL-4-CARBONIL]-PIPERIDIN-4-IL}-1,3,7-TRIAZA-ESPIRO-[4,4]NONANO-2,4-DIONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PREPARACION. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR CCR2 Y/O ANTAGONISTA DEL RECEPTOR CCR5 Y ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES DE COMPONENTE INFLAMATORIO, TAL COMO ARTRITIS, ASMA, ESCLEROSIS MULTIPLE, ENTRE OTROS
PE2008001255A 2007-07-26 2008-07-24 Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5 PE20090893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113173 2007-07-26

Publications (1)

Publication Number Publication Date
PE20090893A1 true PE20090893A1 (es) 2009-07-15

Family

ID=39816951

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001255A PE20090893A1 (es) 2007-07-26 2008-07-24 Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5

Country Status (15)

Country Link
US (1) US7977358B2 (es)
EP (1) EP2182953A2 (es)
JP (1) JP2010534631A (es)
KR (1) KR20100039416A (es)
CN (1) CN101765430A (es)
AR (1) AR067674A1 (es)
AU (1) AU2008280186A1 (es)
BR (1) BRPI0813836A2 (es)
CA (1) CA2693187A1 (es)
CL (1) CL2008002161A1 (es)
PE (1) PE20090893A1 (es)
RU (1) RU2010106397A (es)
SG (1) SG175583A1 (es)
TW (1) TW200911785A (es)
WO (1) WO2009013211A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
PL2163543T3 (pl) 2007-05-18 2015-06-30 Shionogi & Co Heterocykliczna pochodna zawierająca azot o aktywności hamującej dehydrogenazę 11-beta-hydroksysteroidową typu I
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
BRPI0923051B1 (pt) 2008-12-19 2022-07-19 Centrexion Therapeutics Corporation Pirimidin-4-carboxamidas cíclicas como antagonistas do receptor de ccr2 para o tratamento de inflamação, asma e copd, seu uso, formulação e combinação farmacêutica que os compreende
KR101530234B1 (ko) 2009-12-17 2015-06-19 베링거 인겔하임 인터내셔날 게엠베하 신규한 ｃｃｒ２ 수용체 길항제 및 이의 용도
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2012130633A1 (en) * 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
US9682953B2 (en) 2011-09-23 2017-06-20 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
US9289365B2 (en) * 2011-10-24 2016-03-22 Avon Products, Inc. Compositions and methods for stimulating collagen synthesis in the skin
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
SG11201605559VA (en) 2014-01-06 2016-08-30 Algomedix Inc Trpa1 modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
EP3227282B1 (en) * 2014-12-02 2019-04-03 F.Hoffmann-La Roche Ag Novel piperidine derivatives
US20180042234A1 (en) 2015-03-19 2018-02-15 E I Du Pont De Nemours And Company Fungicidal pyrazoles
CN108026087B (zh) 2015-07-02 2021-06-04 中枢疗法公司 氨基嘧啶甲酮衍生物的柠檬酸盐
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10391987B2 (en) * 2017-05-24 2019-08-27 Trw Automotives U.S. Llc Method for controlling a vehicle
TWI846654B (zh) 2018-11-06 2024-06-21 美商富曼西公司 經取代之甲苯基殺真菌劑
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
UY39189A (es) 2020-05-06 2021-12-31 Fmc Corp Fungicidas de tolilo sustituido y sus mezclas
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6140266A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピラゾ−ル誘導体
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5987135A (en) 1997-07-25 1999-11-16 Prc Inc. System and method for controlling and monitoring remote distributed processing system
MXPA02005465A (es) * 1999-12-03 2003-10-15 Ono Pharmaceutical Co Derivados de triazaspiro(5.5)undecano y composiciones farmaceuticas que los comprenden, como un ingrediente activo.
AU2002344951A1 (en) 2001-07-02 2003-01-21 Boehringer Ingelheim International Gmbh Substituted piperazine and diazepanes as histamine h3 receptor agonists
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
TWI262077B (en) 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JP2006519755A (ja) 2002-11-20 2006-08-31 ロレアル ピラゾール−カルボキシアミドを含有する毛髪の手入れ用又は睫毛用の組成物、毛髪及び睫毛の成長を刺激し、及び／又は抜毛を防止するためのそれらの使用
CA2512886A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
DE10315572A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7576089B2 (en) * 2003-12-18 2009-08-18 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
BRPI0507586A (pt) * 2004-02-10 2007-07-03 Hoffmann La Roche moduladores de receptor de quimiocina ccr5
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
EP1762568A1 (en) 2004-07-01 2007-03-14 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
CA2578261A1 (en) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CN101282936B (zh) * 2005-10-07 2012-05-16 橘生药品工业株式会社 氮化杂环化合物及包含其的药物组合物
CA2673359A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators

Also Published As

Publication number Publication date
TW200911785A (en) 2009-03-16
KR20100039416A (ko) 2010-04-15
WO2009013211A2 (en) 2009-01-29
CL2008002161A1 (es) 2009-05-22
WO2009013211A3 (en) 2009-04-23
CA2693187A1 (en) 2009-01-29
AR067674A1 (es) 2009-10-21
US20090029963A1 (en) 2009-01-29
JP2010534631A (ja) 2010-11-11
US7977358B2 (en) 2011-07-12
BRPI0813836A2 (pt) 2015-01-06
EP2182953A2 (en) 2010-05-12
CN101765430A (zh) 2010-06-30
RU2010106397A (ru) 2011-09-10
SG175583A1 (en) 2011-11-28
AU2008280186A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
PE20090893A1 (es) Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5
KR101919680B1 (ko) 신규한 피롤리딘 화합물 및 멜라노코르틴 수용체 아고니스트로서의 용도
RU2017123114A (ru) 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
PE20081783A1 (es) Nuevas 2-aminooxazolinas como ligandos de taar1
PE20070112A1 (es) Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos
PE20080889A1 (es) Aminometil-4-imidazoles
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20090775A1 (es) Nuevos derivados de biarilo
PE20080274A1 (es) Derivados de dioxo-alcanos y dioxo-alquenos sustituidos como moduladores del receptor vanilloide subtipo 1 (trpv1)
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
AR058919A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del snc.
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
PE20110410A1 (es) Derivado de 7-piperidinoalquil-3,4-dihidroquinolona
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20110793A1 (es) Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona
MA33675B1 (fr) Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1
KR20110079847A (ko) 7-하이드록시-벤조이미다졸-4-일-메타논 유도체 및 이를 함유하는 ｐｂｋ 저해제
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten

Legal Events

Date Code Title Description
FC Refusal